Lymphocyte activation gene 3

Drug Profile

Lymphocyte activation gene 3

Alternative Names: LAG-3

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator Merck Serono
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Transplant rejection

Most Recent Events

  • 01 Mar 2000 Suspended-Preclinical for Transplant rejection in USA (Parenteral)
  • 01 Mar 2000 Suspended-Preclinical for Autoimmune disorders in USA (Parenteral)
  • 08 Dec 1998 Preclinical development for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top